Skip to main content

A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up

Acta Neuropathologica volume 126, pages 123–135 (2013)Cite this article

Abstract

Pituitary adenomas are currently classified by histological, immunocytochemical and numerous ultrastructural characteristics lacking unequivocal prognostic correlations. We investigated the prognostic value of a new clinicopathological classification with grades based on invasion and proliferation. This retrospective multicentric case–control study comprised 410 patients who had surgery for a pituitary tumour with long-term follow-up. Using pituitary magnetic resonance imaging for diagnosis of cavernous or sphenoid sinus invasion, immunocytochemistry, markers of the cell cycle (Ki-67, mitoses) and p53, tumours were classified according to size (micro, macro and giant), type (PRL, GH, FSH/LH, ACTH and TSH) and grade (grade 1a: non-invasive, 1b: non-invasive and proliferative, 2a: invasive, 2b: invasive and proliferative, and 3: metastatic). The association between patient status at 8-year follow-up and age, sex, and classification was evaluated by two multivariate analyses assessing disease- or recurrence/progression-free status. At 8 years after surgery, 195 patients were disease-free (controls) and 215 patients were not (cases). In 125 of the cases the tumours had recurred or progressed. Analyses of disease-free and recurrence/progression-free status revealed the significant prognostic value (p < 0.001; p < 0.05) of age, tumour type, and grade across all tumour types and for each tumour type. Invasive and proliferative tumours (grade 2b) had a poor prognosis with an increased probability of tumour persistence or progression of 25- or 12-fold, respectively, as compared to non-invasive tumours (grade 1a). This new, easy to use clinicopathological classification of pituitary endocrine tumours has demonstrated its prognostic worth by strongly predicting the probability of post-operative complete remission or tumour progression and so could help clinicians choose the best post-operative therapy.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Amar AP, Hinton DR, Krieger MD, Weiss MH (1999) Invasive pituitary adenomas: significance of proliferation parameters. Pituitary 2(2):117–122

    PubMed  Article  CAS  Google Scholar 

  2. Asa SL (2011) Tumors of the Pituitary Gland AFIP Fascicle 15/4. 1st edn. p 275. ISBN: 9781933477152

  3. Barker FG 2nd, Klibanski A, Swearingen B (2003) Transsphenoidal surgery for pituitary tumors in the United States, 1996–2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metab 88(10):4709–4719

    PubMed  Article  CAS  Google Scholar 

  4. Breslow NE, Day NE (1980) Statistical methods in cancer research. In: The analysis of case-control studies, vol I, issue number 32. IARC Sci Publ, Lyon, pp 5–338

  5. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert M-H, Prévot V, Lassalle P, Trouillas J, Delehedde M, Maurage C-A (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22(6):757–764

    PubMed  Article  CAS  Google Scholar 

  6. Cottier J-P, Destrieux C, Brunereau L, Bertrand P, Moreau L, Jan M, Herbreteau D (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215(2):463–469

    PubMed  CAS  Google Scholar 

  7. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege. Belgium. J Clin Endocrinol Metab 91(12):4769–4775

    Article  CAS  Google Scholar 

  8. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107

    PubMed  Article  CAS  Google Scholar 

  9. Dubois S, Guyetant S, Menei P, Rodien P, Illouz F, Vielle B, Rohmer V (2007) Relevance of Ki-67 and prognostic factors for recurrence/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157(2):141–147

    PubMed  Article  CAS  Google Scholar 

  10. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf) 72(3):377–382

    Article  Google Scholar 

  11. Figarella-Branger D, Trouillas J (2006) The new WHO classification of human pituitary tumors: comments. Acta Neuropathol 111(1):71–72

    PubMed  Article  Google Scholar 

  12. Francois P, Travers N, Lescanne E, Arbeille B, Jan M, Velut S (2010) The interperiosteo-dural concept applied to the perisellar compartment: a microanatomical and electron microscopic study. J Neurosurg 113(5):1045–1052

    PubMed  Article  Google Scholar 

  13. Fusco A, Zatelli MC, Bianchi A, Cimino V, Tilaro L, Veltri F, Angelini F, Lauriola L, Vellone V, Doglietto F, Ambrosio MR, Maira G, Giustina A, degli Uberti EC, Pontecorvi A, De Marinis L (2008) Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas. J Clin Endocrinol Metab 93(7):2746–2750

    PubMed  Article  CAS  Google Scholar 

  14. Galland F, Lacroix L, Saulnier P, Dessen P, Meduri G, Bernier M, Gaillard S, Guibourdenche J, Fournier T, Evain-Brion D, Bidart JM, Chanson P (2010) Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis. Endocr Relat Cancer 17(2):361–371

    PubMed  Article  CAS  Google Scholar 

  15. Gejman R, Swearingen B, Hedley-Whyte ET (2008) Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol 39(5):758–766

    PubMed  Article  CAS  Google Scholar 

  16. Grossman AB (2006) The 2004 World Health Organization classification of pituitary tumors: is it clinically helpful? Acta Neuropathol (Berl) 111(1):76–77

    Article  Google Scholar 

  17. Heaney AP (2011) Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649–3660

    PubMed  Article  CAS  Google Scholar 

  18. Honegger J, Prettin C, Feuerhake F, Petrick M, Schulte-Monting J, Reincke M (2003) Expression of Ki-67 antigen in nonfunctioning pituitary adenomas: correlation with growth velocity and invasiveness. J Neurosurg 99(4):674–679

    PubMed  Article  Google Scholar 

  19. Horvath E, Kovacs K, Smyth HS, Cusimano M, Singer W (2005) Silent adenoma subtype 3 of the pituitary—immunohistochemical and ultrastructural classification: a review of 29 cases. Ultrastruct Pathol 29(6):511–524

    PubMed  Article  CAS  Google Scholar 

  20. Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, Santoro A, Faticanti Scucchi L, Gulino A, Cantore G (2002) A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 9(2):103–113

    PubMed  Article  CAS  Google Scholar 

  21. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089–3099

    PubMed  Article  CAS  Google Scholar 

  22. Knosp E, Kitz K, Perneczky A (1989) Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67. Neurosurgery 25(6):927–930

    PubMed  Article  CAS  Google Scholar 

  23. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33(4):610–617 (discussion 617–618)

    PubMed  Article  CAS  Google Scholar 

  24. Kovacs K, Horvath E, Ezrin C (1977) Pituitary adenomas. Pathol Annu 12(Pt 2):341–382

    PubMed  Google Scholar 

  25. Kovacs K, Scheithauer B, Horvath E, Lloyd RV (1996) The WHO classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 78:502–510

    PubMed  Article  CAS  Google Scholar 

  26. Laws ER Jr, Lopes MB (2006) The new WHO classification of pituitary tumors: highlights and areas of controversy. Acta Neuropathol 111(1):80–81

    PubMed  Article  Google Scholar 

  27. Lloyd RV, Kovacs K, Young Jr WF, Farrel WE, Asa SL, Trouillas J, Kontogeorgos G, Sano T, Scheithauer B, Horvath E (2004) Pituitary tumours : introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Tumours of the pituitary, chapter 1. Pathology and genetics of tumours of endocrine organs. World Hearth Organization Classification of Tumours. IARC Press, Lyon, pp 10–13

  28. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB, Pieralli S, Giovanelli M (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108(3):525–532

    PubMed  Article  Google Scholar 

  29. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, Wierman ME, Kleinschmidt-DeMasters BK (2011) Giant pituitary adenomas: pathologic-radiographic correlations and lack of role for p53 and MIB-1 labeling. Am J Surg Pathol 35(8):1204–1213

    PubMed  Article  Google Scholar 

  30. McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 41(10):1133–1148

    PubMed  Article  CAS  Google Scholar 

  31. Meij BP, Lopes MB, Ellegala DB, Alden TD, Laws ER Jr (2002) The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. J Neurosurg 96(2):195–208

    PubMed  Article  Google Scholar 

  32. Nose V, Ezzat S, Horvath E, Kovacs K, Laws ER, Lloyd R, Lopes MB, Asa SL (2011) Protocol for the examination of specimens from patients with primary pituitary tumors. Arch Pathol Lab Med 135(5):640–646

    PubMed  Google Scholar 

  33. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M, Yamada S (2008) Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocr Pathol 19(2):82–91

    PubMed  Article  Google Scholar 

  34. Pack SD, Qin LX, Pak E, Wang Y, Ault DO, Mannan P, Jaikumar S, Stratakis CA, Oldfield EH, Zhuang Z, Weil RJ (2005) Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43(1):72–82

    PubMed  Article  CAS  Google Scholar 

  35. R Development Core Team (2009) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http://www.R-project.org

  36. Ramirez C, Cheng S, Vargas G, Asa SL, Ezzat S, Gonzalez B, Cabrera L, Guinto G, Mercado M (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97(5):1745–1751

    PubMed  Article  CAS  Google Scholar 

  37. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) 76(6):769–775

    Article  CAS  Google Scholar 

  38. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592–4599

    PubMed  Article  CAS  Google Scholar 

  39. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95(4):1708–1716

    PubMed  Article  CAS  Google Scholar 

  40. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing’s disease. Eur J Endocrinol 163(1):35–43

    PubMed  Article  CAS  Google Scholar 

  41. Rickert CH, Dockhorn-Dworniczak B, Busch G, Moskopp D, Albert FK, Rama B, Paulus W (2001) Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathol 102(6):615–620

    PubMed  CAS  Google Scholar 

  42. Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol 102(2):117–120

    PubMed  CAS  Google Scholar 

  43. Righi A, Agati P, Sisto A, Frank G, Faustini-Fustini M, Agati R, Mazzatenta D, Farnedi A, Menetti F, Marucci G, Foschini MP (2012) A classification tree approach for pituitary adenomas. Hum Pathol 43(10):1627–1637

    PubMed  Article  CAS  Google Scholar 

  44. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401

    PubMed  Article  CAS  Google Scholar 

  45. Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83

    PubMed  Article  Google Scholar 

  46. Saeger W, Ludecke B, Ludecke DK (2008) Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas. Exp Clin Endocrinol Diabetes 116(2):80–85

    PubMed  Article  CAS  Google Scholar 

  47. Saeger W, Ludecke DK, Buchfelder M, Fahlbusch R, Quabbe HJ, Petersenn S (2007) Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. Eur J Endocrinol 156(2):203–216

    PubMed  Article  CAS  Google Scholar 

  48. Salehi F, Agur A, Scheithauer BW, Kovacs K, Lloyd RV, Cusimano M (2009) Ki-67 in pituitary neoplasms: a review—part I. Neurosurgery 65(3):429–437 (discussion 437)

    PubMed  Article  Google Scholar 

  49. Scheithauer BW, Kovacs KT, Laws ER Jr, Randall RV (1986) Pathology of invasive pituitary tumors with special reference to functional classification. J Neurosurg 65(6):733–744

    PubMed  Article  CAS  Google Scholar 

  50. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56(5):1066–1074

    PubMed  Google Scholar 

  51. Solcia E, Klöppel G, Sobin L (2000) Histological classification of adenohypophyseal tumours. Histological classification of endocrine tumours. Springer, Berlin

    Book  Google Scholar 

  52. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99–106

    PubMed  Article  CAS  Google Scholar 

  53. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr (1996) p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38(4):765–770

    PubMed  Article  CAS  Google Scholar 

  54. Trouillas J, Cure M, Lheritier M, Guichard Y, Girod C (1974) Essai de classification cytofonctionnelle de 19 adénomes hypophysaires d’après des données histologiques, immunocytochimiques, biométriques et ultrastructurales. Rev Oto-Neuro-Ophtalmol 47(3):223–236

    Google Scholar 

  55. Trouillas J, Daniel L, Guigard MP, Tong S, Gouvernet J, Jouanneau E, Jan M, Perrin G, Fischer G, Tabarin A, Rougon G, Figarella-Branger D (2003) Polysialylated neural cell adhesion molecules expressed in human pituitary tumors and related to extrasellar invasion. J Neurosurg 98(5):1084–1093

    PubMed  Article  CAS  Google Scholar 

  56. Trouillas J, Girod C (1996) Pathology of pituitary adenomas. In: Landolt AM, Vance ML, Reilly PL (eds) Pituitary adenomas. Churchill Livingstone, New York, pp 27–46

    Google Scholar 

  57. Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Verges B, Chabre O, Calender A (2008) Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol 32(4):534–543

    PubMed  Article  Google Scholar 

  58. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14(3):887–900

    PubMed  Article  CAS  Google Scholar 

  59. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol 326(1–2):30–39

    PubMed  Article  CAS  Google Scholar 

  60. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J (2011) Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21(5):533–543

    PubMed  CAS  Google Scholar 

  61. Wolfsberger S, Knosp E (2006) Comments on the WHO 2004 classification of pituitary tumors. Acta Neuropathol 111(1):66–67

    PubMed  Article  Google Scholar 

  62. Zada G, Woodmansee WW, Ramkissoon S, Amadio J, Nose V, Laws ER Jr (2011) Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J Neurosurg 114(2):336–344

    PubMed  Article  Google Scholar 

  63. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S (1999) Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas. J Clin Endocrinol Metab 84(2):761–767

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

We thank Emily Witty from Angloscribe for help with the translation into English, A. Reynaud for her excellent technical assistance, P. Gérardi for typing the manuscript, Dr David Forman and Dr Alexandre Vasiljevic for helpful criticisms. Co-authors of HYPOPRONOS are Barlier A., Bernier M., Bonnet F., Borson-Chazot F., Brassier G., Caulet-Maugendre S., Chabre O., Chanson P., Cottier JF., Delemer B., Delgrange E., Di Tommaso L., Eimer S., Gaillard S., Jan M., Girard JJ., Lapras V., Loiseau H., Passagia JG., Patey M., Penfornis A., Poirier JY., Perrin G., Tabarin A. This work was supported by grants from the Ministère de la Santé (Programme Hospitalier de Recherche Clinique National no 27-43, HYPOPRONOS) and research contracts with the Institut National de la Santé et de la Recherche Médicale and the Ligue Contre le Cancer Rhône-Alpes.

Conflict of interest

The authors have nothing to disclose.

Author information

Authors and Affiliations

  1. Université Lyon 1, Université de Lyon, Lyon, France

    Jacqueline Trouillas, Pascal Roy, Emmanuelle Dantony, Carole Auger, Emmanuel Jouanneau, François Chapuis, Laurent Villeneuve & Gérald Raverot

  2. Hospices Civils de Lyon, Lyon, France

    Pascal Roy, Emmanuelle Dantony, Emmanuel Jouanneau, François Chapuis, Laurent Villeneuve & Gérald Raverot

  3. INSERM, UMR-S1028, Lyon Neuroscience Research Center, Oncoflam Team, Lyon, 69372, France

    Carole Auger, Emmanuel Jouanneau & Gérald Raverot

  4. Service de Biostatistique, Hospices Civils de Lyon, Lyon, France

    Pascal Roy & Emmanuelle Dantony

  5. CNRS; UMR 5558, Equipe Biostatistique Santé, Pierre-Bénite, France

    Pascal Roy & Emmanuelle Dantony

  6. Service de Neurochirurgie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

    Emmanuel Jouanneau

  7. Pôle Information Médicale, Unité de Recherche Clinique, Hospices Civils de Lyon, Lyon, France

    François Chapuis & Laurent Villeneuve

  8. Fédération d’Endocrinologie, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France

    Gérald Raverot

  9. Département d’Anatomie et de Cytologie Pathologiques, Centre Hospitalo-Universitaire de Grenoble, Grenoble, France

    Nathalie Sturm

  10. Université Lille Nord de France, Lille, France

    Christine Cortet-Rudelli, Richard Assaker, Aurélie Cornelius & Claude-Alain Maurage

  11. Centre Hospitalo-Universitaire de Lille, Lille, France

    Christine Cortet-Rudelli, Richard Assaker, Aurélie Cornelius & Claude-Alain Maurage

  12. Département d’Endocrinologie, Centre Hospitalo-Universitaire de Lille, Lille, France

    Christine Cortet-Rudelli

  13. Service de Neurochirurgie, Centre Hospitalo-Universitaire de Lille, Lille, France

    Richard Assaker

  14. INSERM U837, Lille, 59800, France

    Claude-Alain Maurage

  15. Laboratoire d’Anatomie Pathologique, Centre Hospitalo-Universitaire de Lille, Lille, France

    Claude-Alain Maurage

  16. Laboratoire d’Anatomie et Cytologie Pathologiques, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France

    Gabriel Viennet

  17. Service de Radiologie, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France

    Jean-François Bonneville

  18. Service d’Endocrinologie, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire de Besançon, Besançon, France

    François Mougel

  19. Aix-Marseille Université, Marseille, France

    Thierry Brue, Henry Dufour & Dominique Figarella-Branger

  20. Service d’Endocrinologie, Diabète et Maladies Métaboliques, Hôpital de la Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France

    Thierry Brue

  21. Unité Mixte de Recherche 7286, Faculté de Médecine de Marseille, Centre de Recherche en Neurobiologie et Neurophysiologie de Marseille (CRN2M), Centre National de la Recherche Scientifique, Aix-Marseille Université, 13284, Marseille, France

    Thierry Brue

  22. Centre de Référence des Maladies Rares d’Origine Hypophysaire, Assistance Publique-Hôpitaux de Marseille (APHM), Hôpital de la Timone, 13005, Marseille, France

    Thierry Brue

  23. Département de Neurochirurgie, Hôpital de la Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France

    Henry Dufour

  24. Service d’Anatomie Pathologique et de Neuropathologie, Hôpital de la Timone, Assistance-Publique Hôpitaux de Marseille, Marseille, France

    Dominique Figarella-Branger

  25. Service de Neurochirurgie, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France

    Patrick François

  26. Université Rennes 1, Rennes, France

    Françoise Galland

  27. Service d’Endocrinologie Diabétologie, Hôpital Sud, Rennes, France

    Françoise Galland

  28. Centre de Pathologie Est, Hospices Civils de Lyon, Groupement Hospitalier Est, Lyon, France

    Jacqueline Trouillas

  29. INSERM, UMR-S1028, Lyon Neuroscience Research Center, Oncoflam Team, Rue Guillaume Paradin, Lyon Cedex 08, 69372, France

    Jacqueline Trouillas

Authors
  1. Jacqueline Trouillas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pascal Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nathalie Sturm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Emmanuelle Dantony
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christine Cortet-Rudelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gabriel Viennet
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jean-François Bonneville
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Richard Assaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carole Auger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Thierry Brue
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Aurélie Cornelius
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Henry Dufour
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Emmanuel Jouanneau
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Patrick François
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Françoise Galland
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. François Mougel
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. François Chapuis
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Laurent Villeneuve
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Claude-Alain Maurage
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Dominique Figarella-Branger
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Gérald Raverot
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

The members of HYPOPRONOS

Corresponding author

Correspondence to Jacqueline Trouillas.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Trouillas, J., Roy, P., Sturm, N. et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126, 123–135 (2013). https://doi.org/10.1007/s00401-013-1084-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00401-013-1084-y

Keywords

  • Classification
  • Pituitary tumour
  • Pituitary adenoma